Zobrazeno 1 - 10
of 4 578
pro vyhledávání: '"S. Shak"'
Publikováno v:
Cancer Research. 81:GS4-10
Background: The 21-gene recurrence score (RS) provides prognostic information for distant recurrence (DR) and predictive information for chemotherapy (CT) benefit in early breast cancer, whereas clinicopathologic features provide only prognostic info
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfc69d2ad4fc049ba41ddc15aa931a07
https://doi.org/10.1158/1538-7445.sabcs20-gs4-10
https://doi.org/10.1158/1538-7445.sabcs20-gs4-10
Autor:
EP Winer, S Shak, KS Albain, Gabriel N. Hortobagyi, GW Sledge, Valentina I. Petkov, Norman Wolmark, Debbie M Jakubowski, Eleftherios P. Mamounas
Publikováno v:
Cancer Research. 79:P3-11
Introduction: The 21-gene Breast Recurrence Score® (RS) in the randomized NSABP B-20, SWOG S8814, and TAILORx studies predicted chemotherapy (CT) benefit for pts with N0 and N+ disease. Endocrine therapy was not inferior to chemoendocrine therapy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae4d62d5b13e6baf86ee61cd184316fb
https://doi.org/10.1158/1538-7445.sabcs18-p3-11-02
https://doi.org/10.1158/1538-7445.sabcs18-p3-11-02
Autor:
Rachel Wuerstlein, Hans Kreipe, Benno Nuding, Michael J. Clemens, S Shak, Friedrich Feuerhake, Matthias Christgen, Oleg Gluz, Fred Heinisch, Ronald E. Kates, T. Reimer, Monika Graeser, Cornelia Kolberg-Liedtke, Ulrike Nitz, Nadia Harbeck, Wolfram Malter
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2020)
Breast Cancer Research, Vol 22, Iss 1, Pp 1-9 (2020)
Background The presence of tumor-infiltrating lymphocytes has been associated with prognosis and chemotherapy response, particularly in high-risk breast cancer subtypes. There is limited data so far as to (i) how tumor-infiltrating lymphocyte (TIL) m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6daae61ccbdaf3c444c774553860d40
https://doi.org/10.1186/s13058-020-01283-w
https://doi.org/10.1186/s13058-020-01283-w
Autor:
Matthias Christgen, Toralf Reimer, H.H. Kreipe, A Pollmanns, A. Stefek, Rachel Wuerstlein, O Gluz, C Chao, Benno Nuding, S Shak, Michael R. Clemens, Wolfram Malter, U. Nitz, Doris Augustin, R Kates, Nadia Harbeck, F Lorenz-Salehi, Christoph Uleer
Publikováno v:
Cancer Research. 78:P1-06
Background: Elderly breast cancer (BC) patients (pts) have been reported to have worse BC-related outcome than younger pts, even within clinical trials such as TEAM. Shak et al. recently showed in a large SEER data analysis that in the high 21-gene r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9fb3a4ddab152d45c70530013b8a5b1
https://doi.org/10.1158/1538-7445.sabcs17-p1-06-06
https://doi.org/10.1158/1538-7445.sabcs17-p1-06-06
Publikováno v:
Cancer Research. 77:P6-09
Evaluating the merits of a genomic assay includes measuring analytic and clinical validity, and establishing clinical utility—a property that is not consistently defined. One definition of clinical utility that has gained traction is “the balance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e66c9ba601a191518a6ad2c611f9c9df
https://doi.org/10.1158/1538-7445.sabcs16-p6-09-08
https://doi.org/10.1158/1538-7445.sabcs16-p6-09-08
Autor:
Matthias Christgen, Michael Hauptmann, O Gluz, Rick Baehner, Hans Kreipe, Monika Graeser, Jochem Potenberg, Kerstin Luedtke-Heckenkamp, S Shak, Bahriye Aktas, Ronald E. Kates, Nadia Harbeck, Helmut Forstbauer, Michael Braun, Ulrike Nitz, Sherko Kuemmel, Eva-Maria Grischke, Christoph Uleer, Raquel von Schumann, Rachel Wuerstlein, Claudia Schumacher, Maren Darsow
Publikováno v:
Cancer Research. 81:GS4-03
Background: Pathological complete response (pCR) is associated with improved outcome in patients with high-risk HR+/HER2- breast cancer (BC) but the use of (neo)adjuvant chemotherapy in early HR+/HER2- BC remains controversial. Oncotype DX / Recurren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::955def68a8e89e9446a4bc2d863a87a2
https://doi.org/10.1158/1538-7445.sabcs20-gs4-03
https://doi.org/10.1158/1538-7445.sabcs20-gs4-03
Autor:
Ana Lluch, Priyanka Sharma, Daniel F. Hayes, Jean-Marc Ferrero, Suzette Delaloge, Lajos Pusztai, Lori J. Goldstein, Miguel Martín, Emilio Alba, S Shak, Subkhbinder Dhesy-Thind, Manuel Ramos Vasquez, Stephen Chia, Gabriel N. Hortobagyi, Edith A. Perez, Funda Meric-Bernstam, Claudia Arce-Salinas, Julie R. Gralow, Nancy Lin, Kyung Hae Jung, Anne F. Schott, In Hae Park, William E. Barlow, Kevin Kalinsky, Danika L. Lew, Jieling Miao, Jean-Yves Pierga, Kathy S. Albain, Priya Rastogi, Debu Tripathy, Miguel Gil, Manuel Ruiz Borrego, Etienne Brain
Publikováno v:
Cancer Research. 81:GS3-00
Funding: Supported by National Cancer Institute grants U10CA180888, U10CA180819, U10CA180820, U10CA180821, U10CA180868, U10CA180863; and in part by Susan G. Komen for the Cure® Research Program, The Hope Foundation for Cancer Research, Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64f5bd06a75125628f5a5767d255f239
https://doi.org/10.1158/1538-7445.sabcs20-gs3-00
https://doi.org/10.1158/1538-7445.sabcs20-gs3-00
Autor:
Jochem Potenberg, Wolfram Malter, Helmut Forstbauer, Matthias Christgen, Eva-Maria Grischke, Mathias Warm, Bahriye Aktas, Ronald E. Kates, Claudia Schumacher, Hans Holger Fischer, Benno Nuding, Nadia Harbeck, O Gluz, Maren Darsow, Hans Kreipe, Michael Braun, Rachel Wuerstlein, Katja Krauss, Sherko Kuemmel, S Shak, Marc Thill, Rick Baehner, Ulrike Nitz, Kerstin Luedtke-Heckenkamp, Christoph Uleer, Monika Graeser, Michael Hauptmann
Publikováno v:
Cancer Research. 81:GS4-04
Background: In HR+/HER2- N0 early breast cancer (EBC), patients (pts) with Recurrence Score™ (RS) Methods: 5625 pts were registered and 4691 finally treated by ET (n=2356) or CT (n=2335) within ADAPTHR+/HER2-. ET-trial ITT population comprised 2290
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce57eb50ce3a57599d1b1f86976c9de5
https://doi.org/10.1158/1538-7445.sabcs20-gs4-04
https://doi.org/10.1158/1538-7445.sabcs20-gs4-04
Autor:
Toralf Reimer, F Heinisch, Nadia Harbeck, O Gluz, U. Nitz, Benno Nuding, Matthias Christgen, Michael R. Clemens, Christer Svedman, Ronald E. Kates, Cornelia Liedtke, Friedrich Feuerhake, S Shak, H.H. Kreipe, Stefan Kraemer
Publikováno v:
Cancer Research. 76:P2-07
Introduction: Tumor-infiltrating lymphocytes (TILs) have been associated with prognosis and with chemotherapy response among patients with BC, particularly in presence of high-risk features. The WSG planB trial randomized 2448 patients with HER2- N0/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcdf90d173393c772a8fe453ee48a18f
https://doi.org/10.1158/1538-7445.sabcs15-p2-07-01
https://doi.org/10.1158/1538-7445.sabcs15-p2-07-01
Autor:
D.M. Jakubowski, George W. Sledge, Norman Wolmark, EP Winer, V.I. Petkov, Eleftherios P. Mamounas, Kathy S. Albain, Gabriel N. Hortobagyi, S Shak
Publikováno v:
The Breast. 44:S100-S101
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f44370f84309c6960955b4075693bbdd
https://doi.org/10.1016/s0960-9776(19)30347-9
https://doi.org/10.1016/s0960-9776(19)30347-9